Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Leucine + sildenafil is a fixed-dose combination of the amino acid L-leucine and the phosphodiesterase type 5 (PDE5) inhibitor sildenafil. This investigational therapy was developed to target metabolic diseases such as obesity by modulating energy metabolism. The mechanism involves allosteric activation of sirtuin 1 (SIRT1) by leucine and inhibition of PDE5A by sildenafil, which together are thought to synergistically activate AMP-activated protein kinase (AMPK), SIRT1, and nitric oxide pathways. These pathways play key roles in regulating energy expenditure and fat metabolism. Clinical studies have evaluated this combination for its effects on body weight reduction in obese individuals[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on leucine + sildenafil.